(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization

International Bureau



(43) International Publication Date 26 February 2004 (26.02.2004)

PCT

(10) International Publication Number WO 2004/016601 A1

(51) International Patent Classification⁷: C07D 277/68, 417/12, A61K 31/428, A61P 29/00

(21) International Application Number:

PCT/EP2003/008824

(22) International Filing Date: 8 August 2003 (08.08.2003)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

0218629.4 0220955.9 9 August 2002 (09.08.2002) Gi

10 September 2002 (10.09.2002) G

(71) Applicant (for all designated States except AT, US): NO-VARTIS AG [CH/CH]; Lichtstrasse 35, CH-4056 Basel (CH).

(71) Applicant (for AT only): NOVARTIS PHARMA GMBH [AT/AT]; Brunner Strasse 59, A-1230 Vienna (AT).

(72) Inventors; and

(75) Inventors/Applicants (for US only): CUENOUD, Bernard [CH/CH]; Rue Volaire 7, CH-1005 Lausanne (CII). FAIRHURST, Robin, Alec [GB/GB]; Novartis Horsham Research Centre, Wimblehurst Road, Horsham, West Sussex RH12 5AB (GB).

(74) Agent: GRUBB, Philip; Novartis AG, Corporate Intellectuel Property, CH-4002 Basel (CH).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LT, LU, LV, MA, MD, MK, MN, MX, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SE, SG, SK, SY, TJ, TM, TN, TR, TT, UA, US, UZ, VC, VN, YU, ZA, ZW.


(84) Designated States (regional): Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR).

Published:

— with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: BENZOTHIAZOLE DERIVATIVES HAVING BETA-2-ADRENORECEPTOR AGONIST ACTIVITY



(57) Abstract: Compounds of Formula (I) in free or salt or solvate form, wherein X has the meaning indicated in the specification, are useful for treating conditions that are prevented or alleviated by activation of the B₂-adrenoreceptor. Pharmaceutical compositions that contain the compounds and processes for preparing the compounds are also described.